LFM-A13
| Title | Journal |
|---|---|
| Dissecting the phenotypes of Plk1 inhibition in cancer cells using novel kinase inhibitory chemical CBB2001. | Laboratory investigation; a journal of technical methods and pathology 20121001 |
| Bruton's tyrosine kinase inhibitors: approaches to potent and selective inhibition, preclinical and clinical evaluation for inflammatory diseases and B cell malignancies. | Journal of medicinal chemistry 20120524 |
| Suppression of Etk/Bmx protects against ischemic brain injury. | Cell transplantation 20120101 |
| Toll-like receptor 4-, 7-, and 8-activated myeloid cells from patients with X-linked agammaglobulinemia produce enhanced inflammatory cytokines. | The Journal of allergy and clinical immunology 20120101 |
| Essential role of Stat3 in PI3K-induced oncogenic transformation. | Proceedings of the National Academy of Sciences of the United States of America 20110809 |
| Bruton's tyrosine kinase is required for TLR-dependent heme oxygenase-1 gene activation via Nrf2 in macrophages. | Journal of immunology (Baltimore, Md. : 1950) 20110715 |
| In vitro and in vivo chemosensitizing activity of LFM-A13, a dual-function inhibitor of Bruton's tyrosine kinase and polo-like kinases, against human leukemic B-cell precursors. | Arzneimittel-Forschung 20110101 |
| Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis. | Bioorganic & medicinal chemistry letters 20101101 |
| Tec protein tyrosine kinase inhibits CD25 expression in human T-lymphocyte. | Immunology letters 20100104 |
| ATP competitive inhibitors of D-alanine-D-alanine ligase based on protein kinase inhibitor scaffolds. | Bioorganic & medicinal chemistry 20090201 |
| Tec kinases regulate actin assembly and cytokine expression in LPS-stimulated human neutrophils via JNK activation. | Cellular immunology 20090101 |
| Discovery of new inhibitors of D-alanine:D-alanine ligase by structure-based virtual screening. | Journal of medicinal chemistry 20081211 |
| Bone marrow X kinase-mediated signal transduction in irradiated vascular endothelium. | Cancer research 20080415 |
| Role of different protein tyrosine kinases in fMLP-induced neutrophil transmigration. | Immunobiology 20080101 |
| A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. | Proceedings of the National Academy of Sciences of the United States of America 20071218 |
| Chemosensitizing anti-cancer activity of LFM-A13, a leflunomide metabolite analog targeting polo-like kinases. | Cell cycle (Georgetown, Tex.) 20071215 |
| Characterization of the intracellular mechanisms involved in the antiaggregant properties of cinnamtannin B-1 from bay wood in human platelets. | Journal of medicinal chemistry 20070809 |
| Anti-breast cancer activity of LFM-A13, a potent inhibitor of Polo-like kinase (PLK). | Bioorganic & medicinal chemistry 20070115 |
| Preclinical toxicity and pharmacokinetics of the Bruton's tyrosine kinase-targeting anti-leukemic drug candidate, alpha-cyano-beta-hydroxy-beta-methyl-N- (2,5-dibromophenyl) propenamide (LFM-A13). | Arzneimittel-Forschung 20070101 |
| Large-scale synthesis of GMP grade alpha-cyano-beta-hydroxy-beta-methyl-N-(2,5-dibromophenyl) propenamide (LFM-A13), a new anti-cancer drug candidate. | Arzneimittel-Forschung 20070101 |
| Microsphere-based protease assays and screening application for lethal factor and factor Xa. | Cytometry. Part A : the journal of the International Society for Analytical Cytology 20060501 |
| Roles for phosphoinositide 3-kinases, Bruton's tyrosine kinase, and Jun kinases in B lymphocyte chemotaxis and homing. | European journal of immunology 20060501 |
| Signaling through CD16b in human neutrophils involves the Tec family of tyrosine kinases. | Journal of leukocyte biology 20050801 |
| Dual targeting of Bruton's tyrosine kinase and Janus kinase 3 with rationally designed inhibitors prevents graft-versus-host disease (GVHD) in a murine allogeneic bone marrow transplantation model. | British journal of haematology 20040901 |
| The Btk inhibitor LFM-A13 is a potent inhibitor of Jak2 kinase activity. | Biological chemistry 20040501 |
| In vivo toxicity and antithrombotic profile of the oral formulation of the antileukemic agent, LFM-A13-F. | Arzneimittel-Forschung 20040101 |
| The anti-leukemic Bruton's tyrosine kinase inhibitor alpha-cyano-beta-hydroxy-beta-methyl-N-(2,5-dibromophenyl) propenamide (LFM-A13) prevents fatal thromboembolism. | Leukemia & lymphoma 20030901 |
| Chemotactic factor-induced recruitment and activation of Tec family kinases in human neutrophils. II. Effects of LFM-A13, a specific Btk inhibitor. | Journal of immunology (Baltimore, Md. : 1950) 20030515 |
| BCR targets cyclin D2 via Btk and the p85alpha subunit of PI3-K to induce cell cycle progression in primary mouse B cells. | Oncogene 20030417 |
| Inhibition of host kinase activity altered by the LMP2A signalosome-a therapeutic target for Epstein-Barr virus latency and associated disease. | Antiviral research 20021201 |
| Silencing of Bruton's tyrosine kinase (Btk) using short interfering RNA duplexes (siRNA). | FEBS letters 20020911 |
| In vivo pharmacokinetic features, toxicity profile, and chemosensitizing activity of alpha-cyano-beta-hydroxy-beta- methyl-N-(2,5-dibromophenyl)propenamide (LFM-A13), a novel antileukemic agent targeting Bruton's tyrosine kinase. | Clinical cancer research : an official journal of the American Association for Cancer Research 20020501 |
| Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells. | The Journal of biological chemistry 20020419 |
| Tyrosine kinase inhibitors against EGF receptor-positive malignancies. | Methods in molecular biology (Clifton, N.J.) 20010101 |
| Rational design and synthesis of a novel anti-leukemic agent targeting Bruton's tyrosine kinase (BTK), LFM-A13 [alpha-cyano-beta-hydroxy-beta-methyl-N-(2, 5-dibromophenyl)propenamide]. | The Journal of biological chemistry 19990402 |